Adalimumab is a lab-made antibody that calms an overactive immune response involved in several chronic inflammatory and autoimmune conditions. It belongs to a class of medicines called TNF (tumour necrosis factor) blockers, one of the most widely used biologic medicine classes, covering conditions from rheumatoid arthritis to inflammatory bowel disease. It is a prescription-only, self-injectable medicine that carries a boxed warning.

• Therapeutic Class: Targeted immunomodulator for autoimmune/inflammatory conditions.

• Pharmacological Class: Tumour necrosis factor-alpha (TNF-α) blocker.

• Drug Family: Human IgG1 monoclonal antibodies.

• ATC Classification: L04AB04 (Adalimumab).

Approved: Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and non-infectious intermediate/posterior/pan-uveitis — indications vary somewhat between the originator product and individual biosimilars.

Commonly used for: Patients with moderate to severe chronic inflammatory or autoimmune conditions not adequately controlled by conventional first-line treatments.

Off-label use (only under medical guidance): Sometimes used in other autoimmune or inflammatory conditions under specialist guidance; not routine outside its approved indication set.

● Injection (prefilled syringe or autoinjector pen, subcutaneous): commonly 40 mg/0.4 mL; other strengths (e.g., 10 mg, 20 mg, 80 mg) are available for specific indications, loading doses, or pediatric weight-based dosing.

Adalimumab binds to and blocks a protein called TNF-alpha, a key inflammatory messenger that is overproduced in many autoimmune and inflammatory conditions. By neutralising TNF-alpha, adalimumab reduces the inflammatory cascade responsible for joint damage, skin plaques, or gut inflammation, depending on the condition being treated.

• Standard dose (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis): 40 mg subcutaneously every other week; some patients not on concurrent methotrexate may benefit from weekly dosing.

• Condition-wise dose (Crohn's disease, ulcerative colitis): Typically an initial loading dose (e.g., 160 mg on day 1, followed by 80 mg two weeks later), then 40 mg every other week for maintenance, per specific product labelling.

• Route: Subcutaneous injection, self-administered after training, typically in the thigh or abdomen.

• Missed dose: Take as soon as remembered, then resume the regular dosing schedule; don't double up.

• Overdose: May increase the risk of known side effects such as infection; requires medical attention.

• Common: Injection-site reactions, upper respiratory infections (including sinusitis), headache, and rash.

• Serious: Serious infections (including tuberculosis and invasive fungal infections), lymphoma and other malignancies (particularly noted in children/adolescents), demyelinating disease, cytopenias, worsening or new-onset heart failure, and lupus-like syndrome.

• Emergency symptoms: Signs of serious infection (fever, chills, persistent cough), unusual bruising or bleeding, new numbness/tingling or vision changes (possible demyelinating disease), or worsening shortness of breath/swelling (possible heart failure).

• Recovery advice: Testing for tuberculosis before starting, along with ongoing monitoring for infection throughout treatment, is central to using adalimumab and similar TNF blockers safely.

• Pregnancy: Adalimumab crosses the placenta; used only if clearly needed, with consideration for the timing of any live vaccines in exposed infants.

• Breastfeeding: Discussed with the treating doctor given available safety data.

• Liver disease: Used with routine monitoring; no formal dose adjustment established for hepatic impairment.

• Kidney disease: Used with routine monitoring; no formal dose adjustment established for renal impairment.

• Elderly: Used with particular caution given a generally higher risk of serious infection in this age group.

• Children: Approved for juvenile idiopathic arthritis and certain other pediatric indications, with age- and weight-based dosing, always under specialist care.

● Other biologic DMARDs (e.g., anakinra, abatacept): combining with adalimumab is not recommended due to an increased risk of serious infection without added benefit.

● Other TNF blockers: should not be combined with adalimumab.

● Rituximab: patients previously treated with rituximab who subsequently receive a TNF blocker have shown a higher rate of serious infections.

● Live vaccines: should generally be avoided during treatment; patients should be brought up to date on vaccinations before starting.

● Tuberculosis screening before starting and periodic monitoring for active TB during treatment, even if the initial test was negative.

● Monitoring for signs of infection throughout treatment.

● Periodic complete blood counts, given the risk of cytopenias.

● Assessment for new or worsening heart failure symptoms, and for symptoms suggestive of demyelinating disease or lupus-like syndrome.

Etanercept, Infliximab, Certolizumab pegol, Golimumab (other TNF blockers); Ustekinumab, Secukinumab, Ixekizumab (different mechanism, IL-targeted biologics used in overlapping indications).

Often used alongside methotrexate in rheumatoid arthritis; can be used as monotherapy in many other approved conditions. Not typically combined with other biologic DMARDs or TNF blockers, given increased infection risk without added benefit.

● Rheumatoid Arthritis Medicines

● Inflammatory Bowel Disease Medicines

● TNF Blockers (Biologic Therapies)

1. Exercise In Older Adults With Rheumatoid Arthritis

2. Eat These 9 Foods For Rheumatoid Arthritis

1. https://www.humirapro.com/dosing

2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761071s011lbl.pdf

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.